JenaValve Appoints Dave Haan as Vice President of Clinical Affairs
JenaValve Technology, Inc. has appointed Dave Haan as Vice President of Clinical Affairs to lead the company’s clinical strategy and oversee clinical programs, including the ARTIST trial, following the FDA approval of their Trilogy® Transcatheter Heart Valve (THV) System for severe aortic regurgitation. Haan brings over 25 years of experience in medical devices and a proven track record in regulatory approvals and clinical organization scaling.
IRVINE, Calif., May 12, 2026 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the appointment of Dave Haan as Vice President of Clinical Affairs. Dave will lead the company’s clinical affairs strategy, overseeing the continued execution of JenaValve’s clinical programs — including the ARTIST randomized controlled trial and the JENA-VAD Registry. His appointment strengthens the company’s clinical leadership during a pivotal period of organizational growth and commercial expansion following the recent FDA approval of the Trilogy THV System for symptomatic, severe aortic regurgitation (ssAR).